US publication provides wrong calculation of development costs of cancer drugs
A significant cost component is not taken into account
19-Sep-2017 -
In a recent study, the US physicians Vinay Prasad and Sham Mailankody from clinics in Portland and New York have calculated the average research and development costs for cancer drugs too low. This is demonstrated by methodological deficiencies in their work: the authors base their research on a ...
cancer drugs
drug development